{"id":"https://genegraph.clinicalgenome.org/r/43d52a11-6da2-41ae-b33a-e79b443ef6ffv1.1","type":"EvidenceStrengthAssertion","dc:description":["*HEY2 *was first reported in relation to autosomal dominant congenital heart disease in 2020 (Edwards et al., PMID: 32368696). 9 variants (missense, nonsense, frameshift, in-frame deletion) that have been reported in at least 12 probands in 2 publications (PMIDs: 32820247, 32368696) are included in this curation. The gene shows a dosage effect, with mostly heterozygous cases reported, although there is a family with three homozygotes severely affected and heterozygous individuals with a milder phenotype. The mechanism of pathogenicity appears to be loss-of-function. This gene-disease relationship is also supported by experimental evidence (NCBI fetal expression data, interaction evidence; PMID: 16199874 ).* HEY2* is shown to inhibit *GATA4* and *GATA6 *expression and function. *GATA4* has been classified as definitive for autosomal dominant structural congenital heart disease. *GATA6 *has been classified as definitive for autosomal dominant congenital heart disease with or without pancreatic agenesis or neonatal diabetes. In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Congenital Heart Disease GCEP on the meeting date 7/2/2024 (SOP Version 10).","*HEY2* was first reported in relation to autosomal dominant congenital heart disease in 2020 (Edwards et al., PMID: 32368696). 9 variants (missense, nonsense, frameshift, in-frame deletion) that have been reported in at least 12 probands in 2 publications (PMIDs: 32820247, 32368696) are included in this curation. The gene shows a dosage effect, with mostly heterozygous cases reported, although there is a family with three homozygotes severely affected and heterozygous individuals with a milder phenotype. The mechanism of pathogenicity appears to be loss-of-function. This gene-disease relationship is also supported by experimental evidence (NCBI fetal expression data, interaction evidence; PMID: 16199874 ). *HEY2* is shown to inhibit *GATA4* and *GATA6* expression and function. *GATA4* has been classified as definitive for autosomal dominant structural congenital heart disease. *GATA6* has been classified as definitive for autosomal dominant congenital heart disease with or without pancreatic agenesis or neonatal diabetes. In summary, there is limited evidence to support this gene-disease relationship. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Congenital Heart Disease GCEP on the meeting date 7/2/2024 (SOP Version 10)."],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/43d52a11-6da2-41ae-b33a-e79b443ef6ff","GCISnapshot":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721","calculatedEvidenceStrength":"Limited","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10130","date":"2025-10-10T18:14:51.374Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10130","date":["2024-07-02T16:00:00.000Z","2024-07-02T05:00:00.000Z"],"role":"Approver"}],"curationReasonDescription":"Please note that the total score for genetic evidence should be 3.4 points, and thus the total score for this curation should be 4.4 points. There was an issue in scoring in the interface for one case, as noted in the notes for that case. ","curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e4aaead5-5671-4422-ba2d-343ee4e01de3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e5e9e2b8-f17d-405c-96f1-bb2a445a027b","type":"Finding","dc:description":"According to fetal expression data from NCBI, the gene is very highly expressed in the heart between 11 and 20 weeks gestation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","rdfs:label":"NCBI Fetal Expression (not from this PMID)","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7c8804a3-90d3-4cde-b158-4b9eab24cc2d","type":"EvidenceLine","dc:description":"Interaction with GATA4 and GATA6, both of which have been classified as definitive for congenital heart disease, is demonstrated. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/66070540-a1b4-4d12-9476-6284230e243a","type":"Finding","dc:description":"GATA4 is definitive for autosomal dominant structural CHD. GATA6 is definitive for autosomal dominant CHD with or without pancreatic agenesis or neonatal diabetes.\nPromoter activity of GATA4/6 target gene ANF was inhibited by HEY2 (as well as by HEY1) in luciferase assay in HEK293 cells. Dose-dependent repression by HEY2 of ANF luciferase activity was evident.  In HEY2 homozygous knockout fetal mouse hearts, GATA4 and GATA6 mRNA expression was elevated compared to the wild type.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16199874","rdfs:label":"GATA4/6 interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91648083-5818-4bc2-8dd1-4f85deaa5da7","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91648083-5818-4bc2-8dd1-4f85deaa5da7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/6aa2267e-05b3-4a7e-a0f4-69ffa54ea206","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.668G>T (p.Gly223Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365576622"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/91648083-5818-4bc2-8dd1-4f85deaa5da7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation significantly increased mTBx2 activation compared to the wild type in a luciferase assay using murine H10 cells. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/06464528-0018-4ea1-987d-0ff5dde30ed7","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06464528-0018-4ea1-987d-0ff5dde30ed7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/7efd0970-6f04-4472-acc5-efb98a266a76","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.118_123del (p.Pro40_Thr41del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2832533800"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/203f2721-2379-4c21-b0b9-33693b3c741a","type":"EvidenceLine","dc:description":"This variant is scored at 0.5 * 2 = 1 (for the homozygous probands). It is downgraded from being a loss-of-function variant as it truncates the protein at the end of the 2nd to last exon, and thus is not predicted to undergo nonsense-mediated decay. However the functional analysis was taken into account. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/203f2721-2379-4c21-b0b9-33693b3c741a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/030f3961-73f7-4479-abc5-8ff4b4f02c31","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.318_319del (p.Gly108Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA570416898"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/203f2721-2379-4c21-b0b9-33693b3c741a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qPCR in chorionic villi from the probandâ€™s cells shows lack of expression","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/67a2c995-b0f2-4b4e-98e6-1bf141966e3b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/67a2c995-b0f2-4b4e-98e6-1bf141966e3b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/6fa10de7-c7e1-4a52-aaee-a7f2ad1b2fbc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.289G>A (p.Val97Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365575833"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/67a2c995-b0f2-4b4e-98e6-1bf141966e3b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation significantly increased mTBx2 activation compared to the wild type in a luciferase assay using murine H10 cells. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/402000e1-4aae-41f9-89b5-c5d12c1a0721_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07043f49-02de-4cdc-8700-3976be29327e_proband_segregation","type":"FamilyCosegregation","dc:description":"LOD scores under different assumptions: 7.76, 5.81, -0.81, with respective assumptions: obligate carriers as nocall, phenotypes of in-laws depicted as unknown, phenotypes & genotypes of in-laws predicted as unknown.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","rdfs:label":"p.Gly108Ter family (homozygous and heterozygous cases)","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/07043f49-02de-4cdc-8700-3976be29327e","type":"Family","rdfs:label":"p.Gly108Ter family (homozygous and heterozygous cases)","member":{"id":"https://genegraph.clinicalgenome.org/r/42291f3a-8e58-4da1-83e8-4c4820cf2251","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","rdfs:label":"Proband p.Gly108Ter","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/030f3961-73f7-4479-abc5-8ff4b4f02c31"},"detectionMethod":"Trio genome sequencing done","phenotypeFreeText":"born at 30 weeks, 5 days","phenotypes":["obo:HP_0002623","obo:HP_0001256","obo:HP_0025666","obo:HP_0001629","obo:HP_0007018","obo:HP_0000028","obo:HP_0012020","obo:HP_0004935"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/203f2721-2379-4c21-b0b9-33693b3c741a_variant_evidence_item"}}},"phenotypeFreeText":"the pregnancy was terminated at 16 weeks for two of the three homozygous mutant individuals due to the severity of congenital heart disease","phenotypePositiveAllelePositive":8,"phenotypes":["obo:HP_0001629","obo:HP_0012020","obo:HP_0004415","obo:HP_0004383","obo:HP_0002623","obo:HP_0000822","obo:HP_0004935","obo:HP_0001719"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/42291f3a-8e58-4da1-83e8-4c4820cf2251"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/debd670b-581c-4b6c-adc0-722874af5121","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/debd670b-581c-4b6c-adc0-722874af5121_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/f6c8d48a-9209-4c14-8d02-7ffcb59ae9b0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.400G>A (p.Ala134Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365576095"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/6037b4c7-0440-40ba-8141-0e1a45af97b5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6037b4c7-0440-40ba-8141-0e1a45af97b5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/30d06c81-064c-4414-a54a-e4b162463125","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.203T>C (p.Leu68Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365575626"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6037b4c7-0440-40ba-8141-0e1a45af97b5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutation significantly increased mTBx2 activation compared to the wild type in a luciferase assay using murine H10 cells. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1461d909-9486-407f-844a-d33aa9a78e57","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1461d909-9486-407f-844a-d33aa9a78e57_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820247","allele":{"id":"https://genegraph.clinicalgenome.org/r/df625230-3604-4639-a856-a51eddadef1d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.887C>T (p.Ala296Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365577063"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/dc025396-bd85-4099-9870-58b039cbecf6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dc025396-bd85-4099-9870-58b039cbecf6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32368696","allele":{"id":"https://genegraph.clinicalgenome.org/r/0a311e82-2a70-48dc-9d38-25c1f0a1ce8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012259.3(HEY2):c.397G>T (p.Val133Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA365576089"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.3}],"evidenceStrength":"Limited","sequence":11971,"specifiedBy":"GeneValidityCriteria10","strengthScore":4.8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/jwzQgKuE1kk","type":"GeneValidityProposition","disease":"obo:MONDO_0005453","gene":"hgnc:4881","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_402000e1-4aae-41f9-89b5-c5d12c1a0721-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}